lofexidine has been researched along with Drug Withdrawal Symptoms in 60 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (21.67) | 18.7374 |
1990's | 8 (13.33) | 18.2507 |
2000's | 18 (30.00) | 29.6817 |
2010's | 20 (33.33) | 24.3611 |
2020's | 1 (1.67) | 2.80 |
Authors | Studies |
---|---|
Fogelman, N; Hermes, G; Hyman, SM; Kosten, TR; Sinha, R | 1 |
Darpö, B; Ferber, G; Longstreth, J; Pirner, M | 1 |
Berger, AA; Hasoon, J; Jung, JW; Kassem, H; Kaye, AD; Mousa, M; Patel, A; Urits, I; Virgen, CG; Viswanath, O; Zusman, R | 1 |
Biswas, K; Gorodetzky, CW; Gullo, KL; Martin, PR; Saxon, AJ; Walsh, SL | 1 |
Ali, R; Gowing, L; White, JM | 2 |
Coulton, S; Diaper, AM; Law, FD; Melichar, JK; Myles, JS; Nutt, DJ | 1 |
Assam, PN; Chan, E; Cheok, C; de Souza, NN; Guo, S; Kandasami, G; Koh, PK; Lee, KM; Manning, V; Pangjaya, J; Sultana, R; Wijesinghe, R; Wong, KE; Yang, Y | 1 |
Traynor, K | 1 |
Brooks, T; Doughty, B; Morgenson, D | 1 |
Bryce, C | 1 |
Bisaga, A; Brooks, D; Carpenter, KM; Choi, JC; Dakwar, E; Glass, A; Levin, FR; Mahony, A; Mariani, JJ; Nunes, EV; Pavlicova, M; Sullivan, MA | 1 |
Clinch, T; Gorodetzky, CW; Gullo, K; Mannix, S; Reinders, S; Vernon, MK | 1 |
Ali, R; Farrell, M; Gowing, L; White, JM | 1 |
Ali, R; Gowing, L; Mbewe, D; White, JM | 1 |
Akerele, E; Boardman, K; Collins, J; Davies, DK; Elkashef, A; Fischman, MW; Herman, BH; Kleber, H; Ling, W; McSherry, F; Miotto, K; Montgomery, A; Montoya, I; O'Brien, CP; Walsh, R; Yu, E | 1 |
Chen, HX; Hao, W; Li, J; Li, SX; Liu, TT; Lu, L; Shen, LY; Shi, J; Wang, X; Xu, GZ | 1 |
Hu, M; Huang, M; Kang, L; Li, J; Wang, X | 1 |
Gish, EC; Honey, BL; Johnson, PN; Miller, JL | 1 |
Bramness, J; Gossop, M; Lobmaier, P; Waal, H | 1 |
Day, E; Strang, J | 1 |
Law, F; Melichar, J; O'Shea, J; Praveen, KT | 1 |
Bigelow, GE; Strain, EC; Walsh, SL | 1 |
Bearn, J; Best, D; Beswick, T; Gossop, M; Rees, S; Strang, J | 1 |
Fu, L; Huang, DB; Yu, ZF | 1 |
Cubells, JF; Tang, YL; Zhao, C; Zhao, D | 1 |
Bearn, J; Best, D; Beswick, T; Gossop, M; McCambridge, J; Rees, S; Strang, J | 1 |
Doebrick, C; Kimmerling, A; Kosten, TR; Sinha, R | 1 |
Bleiberg, J; Epstein, DH; Krantz, MJ; Preston, KL; Schmittner, J; Schroeder, JR | 1 |
Comer, SD; Foltin, RW; Haney, M; Hart, CL; Reed, SC; Vosburg, SK | 1 |
Gao, L; Hu, M; Kang, L; Li, B; Li, J; Li, S; Wang, D | 1 |
Geyer, G; Resnick, RB; Washton, AM | 1 |
Dackis, CA; Gold, MS; Washton, AM | 1 |
Resnick, RB; Washton, AM | 2 |
Annitto, WJ; Extein, I; Gold, MS; Pottash, AC; Sweeney, DR | 2 |
Lal, H; Shearman, GT; Ursillo, RC | 1 |
Stewart, AM; Wylie, AS | 1 |
Alcorn, R; Cox, S | 1 |
Greenwood, J; Seivewright, NA | 1 |
Bearn, J; Gossop, M; Strang, J | 2 |
Beckford, H; Kahn, A; Mumford, JP; Rogers, GA | 1 |
Hu, WH; Lin, SK; Strang, J; Su, LW; Tsai, CJ | 1 |
Carnwath, T; Hardman, J | 1 |
Bearn, J; Buntwal, N; Gossop, M; Strang, J | 1 |
Delsignore, R; Di Gennaro, C; Gardini, S; Gerra, G; Giusti, F; Zaimovic, A; Zambelli, U | 1 |
Alcorn, R; Feinmann, C; White, R | 1 |
Ali, RL; Farrell, M; Gowing, LR; White, JM | 1 |
Allen, S; Farrell, M; Gupta, J; Howells, C; Marsden, J; Stillwell, G | 1 |
Cushman, P; Sowers, JR | 1 |
Cook, CC; Lipsedge, MS; Scannell, TD | 1 |
Agren, H | 1 |
Brunning, J; Keaney, FP; Mumford, JP | 1 |
Bonfiglio, JF; Fant, W; Ritschel, WA; Siegel, EG | 1 |
14 review(s) available for lofexidine and Drug Withdrawal Symptoms
Article | Year |
---|---|
A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.
Topics: Analgesics, Opioid; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2020 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Non-Randomized Controlled Trials as Topic; Opioid-Related Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Severity of Illness Index; Substance Withdrawal Syndrome | 2017 |
Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
Topics: Adult; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; United States; United States Food and Drug Administration | 2019 |
Alpha₂-adrenergic agonists for the management of opioid withdrawal.
Topics: Acute Disease; Adrenergic alpha-2 Receptor Agonists; Clonidine; Controlled Clinical Trials as Topic; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2016 |
Buprenorphine for managing opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Female; Humans; Male; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2017 |
Buprenorphine for the management of opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2009 |
Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Clinical Trials as Topic; Clonidine; Humans; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2010 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Support; Substance Withdrawal Syndrome | 2010 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics | 2006 |
The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
Topics: Adult; Baclofen; Clonidine; Drug Therapy, Combination; Electric Stimulation Therapy; Endorphins; Ethanol; Female; Humans; Locus Coeruleus; Male; Methyldopa; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1984 |
Lofexidine and opioid withdrawal.
Topics: Antihypertensive Agents; Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1995 |
What is important in drug misuse treatment?
Topics: Buprenorphine; Clonidine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders; United Kingdom | 1996 |
Alpha2-adrenergic agonists in opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Confidence Intervals; Controlled Clinical Trials as Topic; Humans; Methadone; Narcotics; Odds Ratio; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2002 |
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome | 1986 |
29 trial(s) available for lofexidine and Drug Withdrawal Symptoms
Article | Year |
---|---|
Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Administration, Oral; Adolescent; Adult; Chemoprevention; Clonidine; Craving; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Pilot Projects; Recurrence; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2019 |
Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.
Topics: Adolescent; Adult; Analgesics, Opioid; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Narcotic Antagonists; Substance Withdrawal Syndrome; Young Adult | 2019 |
A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Topics: Adult; Analgesics, Opioid; Animals; Clonidine; Double-Blind Method; Female; Humans; Inpatients; Male; Middle Aged; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; United Kingdom | 2017 |
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Clonidine; Craving; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2017 |
Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Craving; Diazepam; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Opioid-Related Disorders; Pupil; Singapore; Substance Withdrawal Syndrome | 2018 |
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Cannabinoid Receptor Agonists; Clonidine; Craving; Double-Blind Method; Dronabinol; Female; Humans; Male; Marijuana Abuse; Medication Adherence; Middle Aged; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome | 2016 |
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Clonidine; Data Collection; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Substance Abuse Detection; Substance Withdrawal Syndrome; Survival Analysis; Treatment Outcome | 2008 |
A comparative clinical study of the effects of the traditional Chinese medicine Jinniu capsules and lofexidine on acute heroin withdrawal symptoms.
Topics: Adult; Clonidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Heroin Dependence; Humans; Male; Narcotic Antagonists; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult | 2008 |
A study on Fu-Yuan Pellet, a traditional chinese medicine formula for detoxification of heroin addictions.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Clonidine; Drugs, Chinese Herbal; Female; Heroin Dependence; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Narcotic Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2009 |
Outpatient versus inpatient opioid detoxification: a randomized controlled trial.
Topics: Analgesics, Opioid; Clonidine; Female; Heroin; Heroin Dependence; Humans; Inpatients; Male; Methadone; Narcotics; Opioid-Related Disorders; Outcome Assessment, Health Care; Outpatients; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 2011 |
Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naloxone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome | 2003 |
[Clinical observation on effect of modified banxia houpu decoction in treating patients with protracted heroin abstinence syndrome].
Topics: Adolescent; Adult; Clonidine; Drugs, Chinese Herbal; Female; Heroin Dependence; Humans; Male; Narcotic Antagonists; Phytotherapy; Substance Withdrawal Syndrome | 2004 |
In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Clonidine; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome; Treatment Outcome | 2007 |
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Topics: Adult; Behavior, Addictive; Clonidine; Cues; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Stress, Psychological; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome | 2007 |
Hemodynamic and cognitive effects of lofexidine and methadone coadministration: a pilot study.
Topics: Adolescent; Adult; Blood Pressure; Clonidine; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Narcotics; Pilot Projects; Prospective Studies; Substance Withdrawal Syndrome | 2007 |
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Topics: Adrenergic alpha-Agonists; Adult; Affect; Appetite; Attention; Cannabinoids; Clonidine; Double-Blind Method; Dronabinol; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Mental Recall; Psychomotor Performance; Psychotropic Drugs; Secondary Prevention; Sleep; Substance Withdrawal Syndrome | 2008 |
Tai-Kang-Ning, a Chinese herbal medicine formula, alleviates acute heroin withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Heroin Dependence; Humans; Male; Narcotic Antagonists; Severity of Illness Index; Substance Withdrawal Syndrome | 2008 |
Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Clinical Trials as Topic; Clonidine; Humans; Male; Methadone; Methadyl Acetate; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal.
Topics: Adolescent; Adult; Blood Pressure; Clonidine; Double-Blind Method; Female; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Neurologic Examination; Substance Abuse Detection; Substance Withdrawal Syndrome | 1996 |
Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Patient Admission; Substance Withdrawal Syndrome | 1997 |
Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal.
Topics: Adult; Circadian Rhythm; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heroin; Humans; Hypotension, Orthostatic; Male; Narcotic Antagonists; Severity of Illness Index; Substance Withdrawal Syndrome | 1997 |
Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypotension; Male; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors; Treatment Outcome | 1998 |
Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Ambulatory Care; Blood Pressure; Chi-Square Distribution; Clonidine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome | 1998 |
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome | 2000 |
Lofexidine versus clonidine in rapid opiate detoxification.
Topics: Adult; Analysis of Variance; Clonidine; Double-Blind Method; Humans; Inactivation, Metabolic; Male; Naloxone; Opioid-Related Disorders; Opium; Substance Withdrawal Syndrome; Time Factors | 2001 |
Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Double-Blind Method; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Prisons; Substance Withdrawal Syndrome | 2002 |
Alcohol withdrawal syndrome: clinical and hormonal responses to alpha 2-adrenergic agonist treatment.
Topics: Adrenergic alpha-Agonists; Adult; Alcoholism; Catecholamines; Clinical Trials as Topic; Clonidine; Double-Blind Method; Ethanol; Humans; Male; Middle Aged; Prolactin; Substance Withdrawal Syndrome | 1989 |
Another trial that failed.
Topics: Attitude of Health Personnel; Clinical Trials as Topic; Clonidine; Double-Blind Method; Humans; Opioid-Related Disorders; Random Allocation; Research Support as Topic; Substance Withdrawal Syndrome | 1988 |
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome | 1986 |
18 other study(ies) available for lofexidine and Drug Withdrawal Symptoms
Article | Year |
---|---|
FDA approves nonopioid medication for managing opioid withdrawal.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Drug Approval; Humans; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; United States; United States Food and Drug Administration | 2018 |
Lofexidine (Lucemyra) for opioid withdrawal.
Topics: Clonidine; Drug Approval; Drug Interactions; Humans; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; United States; United States Food and Drug Administration | 2018 |
Management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2018 |
Expanded table: Some drugs for management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2018 |
Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonidine; Dose-Response Relationship, Drug; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2019 |
Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification.
Topics: Adult; Clonidine; Factor Analysis, Statistical; Female; Humans; Male; Narcotic Antagonists; Opioid-Related Disorders; Psychometrics; Reproducibility of Results; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2016 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments.
Topics: Clonidine; Humans; Methadone; Narcotic Antagonists; Narcotics; Sleep Wake Disorders; Substance Withdrawal Syndrome; Time Factors | 2003 |
Lofexidine, a clonidine analogue effective in opiate withdrawal.
Topics: Clonidine; Humans; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1981 |
Recent advances in opiate detoxification: clonidine and lofexidine.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Lofexidine blocks acute opiate withdrawal.
Topics: Antihypertensive Agents; Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Lofexidine in abrupt methadone withdrawal.
Topics: Clonidine; Humans; Male; Methadone; Substance Withdrawal Syndrome | 1982 |
Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat.
Topics: Animals; Behavior, Animal; Clonidine; Diarrhea; Dose-Response Relationship, Drug; Humans; Male; Morphine Dependence; Naloxone; Rats; Substance Withdrawal Syndrome | 1980 |
Opiate detoxification with lofexidine.
Topics: Clonidine; Humans; Methadone; Norepinephrine; Substance Withdrawal Syndrome; Time Factors | 1981 |
Lofexidine based regimen for opiate addicts.
Topics: Clonidine; Humans; Opioid-Related Disorders; Pilot Projects; Substance Withdrawal Syndrome | 1995 |
Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine.
Topics: Adult; Buprenorphine; Chi-Square Distribution; Clonidine; Community Health Services; Female; Humans; Logistic Models; Male; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Prospective Studies; Statistics, Nonparametric; Substance Withdrawal Syndrome | 2001 |
Lofexidine in alcohol withdrawal states.
Topics: Attention; Blood Pressure; Clonidine; Ethanol; Female; Humans; Male; Substance Withdrawal Syndrome | 1986 |
Investigation of clonidine and lofexidine for the treatment of barbiturate withdrawal in mice.
Topics: Animals; Barbiturates; Clonidine; Male; Mice; Mice, Inbred DBA; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders | 1985 |